NCT00233883View on ClinicalTrials.gov

WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.

PHASE4CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
HIV Infections
Interventions
DRUG

enfuvirtide [Fuzeon]

90mg sc bid by Biojector 2000 NFID for 4 weeks

DRUG

enfuvirtide [Fuzeon]

"90mg sc bid by 27G1/2 needle/syringe for 4 weeks"

Trial Locations (17)

20009

Washington D.C.

22003

Annandale

30309

Atlanta

33143

South Miami

33334

Fort Lauderdale

48201

Detroit

60612

Chicago

60657

Chicago

63139

St Louis

75246

Dallas

77004

Houston

90022

Los Angeles

90036

Los Angeles

90210

Los Angeles

90813

Long Beach

02215-3318

Boston

27157-1082

Winston-Salem

Sponsors

Collaborators (1)

Trimeris
All Listed Sponsors
collaborator

Trimeris

INDUSTRY

lead

Hoffmann-La Roche

INDUSTRY

NCT00233883 - WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV. | Biotech Hunter | Biotech Hunter